Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

ESSA Pharma Inc (EPIX)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow ESSA Pharma's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
6.32 -0.40    -5.95%
16:00:00 - Closed. Currency in USD ( Disclaimer )
After Hours
6.56
+0.24
+3.80%
16:15:59 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 101,065
  • Bid/Ask: 5.00 / 6.40
  • Day's Range: 6.18 - 6.96
ESSA Pharma 6.32 -0.40 -5.95%

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

EPIX Comments

Write your thoughts about ESSA Pharma Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Chiaretto Calo
Chiaretto Calo Nov 24, 2023 10:33AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ESSA Pharma recently presented some impressive data at the European Society of Medical Oncology 2023 Congress. They've been working on this game-changing drug called masofaniten (previously known as EPI-7386), and the results are turning heads. Masofaniten is a novel androgen receptor inhibitor, a new kind of treatment for prostate cancer that works differently from anything else out there. Prostate cancer is a major issue worldwide, reaching millions of people, and ESSA's approach is innovative. Their drug specifically targets the N-terminal domain of the androgen receptor, a pathway crucial in prostate cancer growth. What's more, this pathway hasn't been targeted by other therapies yet, which positions masofaniten as a potential first-in-class drug. The data from their Phase 1/2 trials is what's really stirring up excitement. In these trials, masofaniten, combined with another drug called enzalutamide, showed deep and durable reductions in prostate-specific antigen (PSA) levels in patients. These reductions are a big indicator of the drug’s effectiveness against metastatic castration-resistant prostate cancer. And guess what? Most of the patients showed significant improvements. The U.S. Food and Drug Administration has granted Fast Track designation to masofaniten for this specific cancer treatment. Plus, ESSA retains all rights to masofaniten globally, which is huge for its valuation and potential profits.
Reply
1 0
Report
Chiaretto Calo
Chiaretto Calo Nov 24, 2023 10:32AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://www.urologytimes.com/view/masofaniten-plus-enzalutamide-shows-promise-in-mcrpc
Reply
1 0
Report
Chiaretto Calo
Chiaretto Calo Nov 24, 2023 10:12AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ESSA Pharma recently presented some impressive data at the European Society of Medical Oncology 2023 Congress. They've been working on this game-changing drug called masofaniten (previously known as EPI-7386), and the results are turning heads. Masofaniten is a novel androgen receptor inhibitor, a new kind of treatment for prostate cancer that works differently from anything else out there. Prostate cancer is a major issue worldwide, reaching millions of people, and ESSA's approach is innovative. Their drug specifically targets the N-terminal domain of the androgen receptor, a pathway crucial in prostate cancer growth. What's more, this pathway hasn't been targeted by other therapies yet, which positions masofaniten as a potential first-in-class drug. The data from their Phase 1/2 trials is what's really stirring up excitement. In these trials, masofaniten, combined with another drug called enzalutamide, showed deep and durable reductions in prostate-specific antigen (PSA) levels in patients. These reductions are a big indicator of the drug’s effectiveness against metastatic castration-resistant prostate cancer. And guess what? Most of the patients showed significant improvements. The U.S. Food and Drug Administration has granted Fast Track designation to masofaniten for this specific cancer treatment. Plus, ESSA retains all rights to masofaniten globally, which is huge for its valuation and potential profits. If masofaniten continues to show promise in its ongoing Phase 2 trials, we could be looking at a significant breakthrough in prostate cancer treatment. And as investors know, breakthroughs like this don't just save lives; they also create substantial financial opportunities.
Reply
1 0
Report
Manuel Martin
Manuel Martin Jan 16, 2020 4:26AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
EPIX @$50 in summer 2020 ?
Reply
1 1
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close

Make Smart Decisions.
Research, evaluate, and invest with unique market insights

Volatile markets create opportunities.
Don’t miss out.

Investing Insights
Investing Insights
Investing Insights

Read More

Invest with knowledge

Leverage the wisdom of financial experts and seize market opportunities.

  • Generate investment ideas based on leading Wall Street analyst recommendations.

  • Research trending stocks using 6 unique market factors.

  • Receive market updates in our Insights Newsletter.

Why Investing Insights

5 ways to boost your research

  • Objective stock score based on 6 market factors

  • Wall Street analyst price targets and ratings

  • Stock sentiment by bloggers, insiders, and financial gurus

  • News sentiment and score for thousands of stocks

  • Simplified screener with 3 ways to research investment ideas

  • Objective stock score based on 6 market factors

  • Wall Street analyst price targets and ratings

  • Stock sentiment by bloggers, insiders, and financial gurus

  • News sentiment and score for thousands of stocks

  • Simplified screener with 3 ways to research investment ideas

  • Objective stock score based on 6 market factors

  • Wall Street analyst price targets and ratings

  • Stock sentiment by bloggers, insiders, and financial gurus

  • News sentiment and score for thousands of stocks

  • Simplified screener with 3 ways to research investment ideas

Stay Ahead. Learn From the Pros.

For the stocks you research, we’ll bring you insights from

  • 6,500 Wall Street analysts

  • 40,000 corporate insiders

  • 7,000 financial bloggers

  • 200 leading hedge funds

  • 100,000 news stories daily

  • 100s of investment ideas

* For the U.S. stock market. We are continually expanding coverage.

Questions & Answers

  • What is Investing Insights?

    Investing Insights is a premium service that provides you with actionable insights from thousands of financial experts that cover the US stock market. Find out which stocks Wall Street analysts, insiders, financial bloggers, hedge fund managers and individual investors are recommending. Investing Insights is available only on our website. Canadian and UK stock markets will soon be added.

  • What is "Smart Score"?

    Smart Score is a powerful scoring system that ranks stocks on a scale of 1-10 based on 6 unique market factors. Smart Score is updated every evening after the market closes, 5 days a week.

  • Can I try Investing Insights for free?

    Yes. You can try Investing Insights for 14 days free of charge.
    The trial period will be followed by a paid subscription. To avoid being charged simply contact our support to cancel the subscription before the trial period ends.
    Please notice that purchases made through PayPal might be subjected to a temporary authorization.

  • How do I cancel my Investing Insights premium subscription?

    In order to cancel your subscription, please contact our support with your registered email or reference number and one of our agents will be happy to assist you.

  • Will I get notified before my subscription renewal?

    Our subscription has automatic renewal, meaning that when you reach the subscription end date, you will be charged automatically and your subscription will be extended. You can cancel your subscription anytime by following the instructions in the answer to the "How do I cancel my Investing Insights subscription" question. The subscription will remain active for the duration of the paid period.

  • What are the available payment methods?

    We accept all major credit cards and debit cards, including Visa, Mastercard, American Express, Discover, JCB, and Diners. Additional payment options may be available in your specific location

Got more questions?

We hope you found the answers you were looking for. You can read more about Insights here. Please go to the Investing Help Center for further information.

By subscribing you agree to TipRanks' Terms and Conditions and Privacy Policy

Powered by
Continue with Google
or
Sign up with Email